On Monday, April 28, the next meeting of the Transparency Council.
AOTMiT: The Transparency Council will evaluate two drugs
Published April 25, 2025 07:14
Źródło: AOTMiT
The agenda includes:
- Preparation of a position paper on the evaluation of the drug Bellix (bilastinum) for the indication: symptomatic treatment of allergic rhinoconjunctivitis (seasonal and year-round) and urticaria. Bellix medicinal product is indicated for use in adults and adolescents (aged 12 years and over).
- Prepare a position paper on the evaluation of the drug Mibrex (rivaroxabanum) for the indication in the prevention of atherosclerotic thrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischemic events.
Source: AOTMiT
